Filing Flows › Intellia Therapeutics (NTLA) › Q1 2025
Intellia Therapeutics (NTLA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Intellia Therapeutics (NTLA) reported revenue of $16.6M for the first quarter 2025 (Q1 2025), -43% from a year earlier and +29% from the quarter before. Operating margin was -726.6%, net loss $114M (687.6% of revenue).
Intellia Therapeutics, Q1 2025: revenue $16.6M (-42% year over year), operating margin -726.6%, net loss $114M, operating cash flow −$149M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.6M | +29% | -43% |
| Operating profit | −$121M | — | — |
| Net earnings | −$114M | — | — |
| Operating cash flow | −$149M | — | — |
What changed
Revenue was $16.6M in Q1 2025, down 43% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $120.8M, an operating margin of -726.6%. Total costs fell 4% while revenue fell 43%. The quarter ended with a net loss of $114.3M, narrower than the previous quarter's $128.9M loss.
Operating cash flow was −$148.9M. Non-cash charges added back $2.5M of depreciation and amortization and $21.8M of share-based compensation. Working capital and other items used $58.9M. Capital expenditures of $735K exceeded it, leaving free cash flow of −$149.7M.
Questions
What was Intellia Therapeutics' revenue in the first quarter 2025?
Intellia Therapeutics (NTLA) reported revenue of $16.6M for the first quarter 2025 (Q1 2025), -43% from a year earlier and +29% from the quarter before.
Was Intellia Therapeutics profitable in the first quarter 2025?
Operating loss was $121M (-726.6% of revenue) and net loss $114M.